Fulcrum had identified inhibitors of p38/ mitogen ... to review existing p38/ MAPK inhibitors and identify losmapimod as a compound with the potential to address the root cause of FSHD by ...

Fulcrum Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2024, reporting a cash position of $241 million, providing a runway into at least 2027. The ...